On-Demand WebinarWith an advanced understanding of human biology, it is now recognized that various diseases are influenced by the immune system. However, many chronic inflammatory diseases and autoimmune-related disorders still lack effective medication for patients. Developing immune-targeting therapies has been challenging due to insufficient knowledge of the underlying disease mechanisms and complex interactions between different cell types. Despite growing interest and advancements in anti-inflammatory therapies, most of these therapies fail in phase 2 clinical trials due to insufficient efficacy. Moreover, modeling inflammation with precision and accuracy requires multicellular disease models in a human-relevant manner, which capture key inflammatory mechanisms including endothelial activation, immune adhesion and recruitment, innate immunity, and target tissue functionality.It becomes clear that better pre-clinical models, which accurately represent inflamed tissue of the human body, are needed to support and improve drug discovery of immune-targeting therapies.Watch this on-demand webinar with Lenie van den Broek (Director Biology Discovery MIMETAS). Gain insights into MIMETAS’ expertise in 3D disease modeling, as well as drug ranking and selection within the field of inflammation. Learn how comprehensive in vitro inflammation models are pivotal in improving drug discovery and establishing more effective treatments for patients. The webinar will explore, among other topics, the immuno-suppressive and stimulatory nature of the macrophages in Inflammatory Bowel Disease (IBD).Webinar highlights:- Case study to confirm mechanism of action and rank antibodies in vascular inflammation assay- The use of complement activated serum for studying inflammation in an immune competent renal model- Capturing IBD-relevant mechanisms in donor-derived multicellular gut organoid models- The benefits of partnering with MIMETAS to accelerate your research and improve the selection of your immunomodulatory compounds